GlassScriptPhysician profile
Clifton C Davis
NPI 1518058973
$1,544.31
in general payments reported to CMS, 2019-2025
10 companies · $288 in 2025
The $288 reported for 2025 was more than what 86% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $29.29 · 2022: $102 · 2023: $393 · 2024: $619 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.73 | 2019-2024 | Trulance, Xifaxan |
| Phathom Pharmaceuticals, INC. | $247.82 | 2024 | Voquezna |
| Intra-Sana Laboratories | $222.99 | 2022-2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Medtronic, INC. | $149.48 | 2023 | Intellis Adaptivestim |
| Ipsen Biopharmaceuticals, INC | $139.29 | 2025 | Iqirvo |
| E.R. Squibb & Sons, L.L.C. | $124.63 | 2024 | Zeposia |
| Gilead Sciences, INC. | $122.83 | 2023 | Vemlidy |
| Novo Nordisk INC | $121.15 | 2025 | Wegovy |
| Biotronik Nro, INC. | $48.39 | 2024-2025 | Prospera |
| Abbvie INC. | $41.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifton Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.